Observational study of people infected with SARS-Cov-2, treated with amantadine.
Pharmacol Rep
; 72(6): 1538-1541, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-842967
ABSTRACT
BACKGROUND:
We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.METHODOLOGY:
In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.RESULTS:
This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.CONCLUSION:
Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Amantadine
/
Ambulatory Care
/
COVID-19 Drug Treatment
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Country/Region as subject:
Mexico
Language:
English
Journal:
Pharmacol Rep
Journal subject:
Pharmacology
Year:
2020
Document Type:
Article
Affiliation country:
S43440-020-00168-1
Similar
MEDLINE
...
LILACS
LIS